export default function VipOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide your body produces naturally in the gut, brain, and immune tissue. It relaxes smooth muscle, dilates blood vessels, modulates immune activity, and regulates GI motility. As an injectable compound, it has a plasma half-life of under two minutes — meaning it&rsquo;s inactivated almost immediately after entering the bloodstream. Community interest is driven largely by CIRS (chronic inflammatory response syndrome) research and immune modulation goals, but the pharmacokinetics make self-administered injection deeply problematic.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; GI Issues or Immune Dysfunction</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I have chronic gut problems or a complicated immune situation, and I&rsquo;ve seen VIP mentioned in the context of gut healing and immune balance. What is it actually doing in my body?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re curious</p>
        <ol className="reta-overview__profile-why">
          <li><strong>VIP is a real and important signal in GI and immune biology</strong><br />VIP nerves in the gut wall regulate motility, fluid secretion, and local immune cell activity. Deficiencies or dysfunction in VIP signaling have been associated with IBS, IBD-related motility problems, and immune dysregulation in the gut. For someone with complex GI issues, the endogenous biology of VIP is genuinely relevant to understanding what might be going wrong.</li>
          <li><strong>The CIRS and biotoxin illness research is why VIP has entered community discussions</strong><br />Researchers studying chronic inflammatory response syndrome from mold or biotoxin exposure have proposed VIP deficiency as part of the pathophysiology, with intranasal VIP being used in some protocols. For people who have been through the CIRS diagnostic and treatment pathway, this is not an abstract pharmacological curiosity — it&rsquo;s a specific clinical hypothesis about their condition.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The CIRS/VIP hypothesis is far from mainstream medicine, and the evidence base for VIP treatment in that context is preliminary and not replicated in large controlled trials. More importantly for anyone considering VIP self-injection: the compound is inactivated within two minutes in circulation, so any injectable protocol claiming sustained systemic effects has a fundamental pharmacokinetic problem that needs explaining. VIP also causes significant vasodilation and blood pressure drops — effects that are rapid and potentially severe at doses above trivial amounts. Net: the endogenous biology is real and interesting; the injectable self-administration path is pharmacologically problematic and potentially dangerous.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; GI-Immune Axis and Performance</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I get GI issues during hard training and my immunity tanks during heavy blocks. I&rsquo;ve seen VIP described as linking gut and immune function. Is there anything useful here for an athlete?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>VIP connects GI motility and immune function in a way that&rsquo;s mechanistically relevant to athletes</strong><br />GI distress during endurance events and post-exercise immune suppression are real athlete problems. VIP&rsquo;s role in regulating gut motility, reducing intestinal inflammation, and modulating immune cell activity touches both. The underlying biology is legitimately relevant to the athlete&rsquo;s situation, even if the therapeutic application is not practical.</li>
          <li><strong>The anti-inflammatory signaling in the gut makes VIP biology interesting for gut health</strong><br />VIP reduces pro-inflammatory cytokine production from gut immune cells and helps maintain mucosal integrity. For an athlete dealing with increased gut permeability or inflammation from heavy training and high food volumes, this endogenous regulatory signal is relevant to understand.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">There is no community or clinical protocol for injectable VIP in athletic recovery that has established safety or efficacy. The two-minute half-life makes any sustained systemic effect from peripheral injection mechanistically implausible without continuous IV delivery — which is a clinical setting, not a self-administration scenario. The vasodilation and blood pressure effects from VIP are dose-dependent and rapid, and hypotension during or after exercise training is a dangerous combination. The right takeaway from VIP biology for an athlete is about gut health interventions that support endogenous VIP function — not injecting VIP itself. Net: mechanistically interesting, practically unavailable as a useful injectable tool.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; CIRS, Immune Modulation, and Neurological Function</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;VIP has receptors in the brain, gut, immune tissue, and lungs. The CIRS research is interesting but controversial. What does the actual biology say about VIP as an immune and neurological modulator, and where does the evidence actually stand?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>VIP receptor distribution is unusually broad, touching systems most peptides don&rsquo;t reach</strong><br />VIP receptors (called VPAC1 and VPAC2) are expressed in T cells, B cells, macrophages, brain neurons, GI smooth muscle, lung tissue, and vascular walls. A compound with this distribution acts as a coordinating signal across multiple physiological systems simultaneously — rare in peptide pharmacology and mechanistically interesting for people thinking about systems-level regulation.</li>
          <li><strong>Aviptadil (synthetic VIP analog) has been in clinical trials for ARDS and COVID-related respiratory failure</strong><br />The existence of a clinical trial program — even with mixed results — demonstrates that VIP analog pharmacology is being taken seriously at the clinical level. The lung-protective and anti-inflammatory effects are the most clinically studied application. Aviptadil is a different compound from native VIP, but the clinical trial program reflects the biological plausibility of therapeutic VIP pathway modulation.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The pharmacokinetic limitation — two-minute plasma half-life — is not a minor detail. It fundamentally limits what any injectable VIP protocol can achieve systemically. Aviptadil was developed precisely because it&rsquo;s more stable; the clinical trials for native VIP are essentially absent. The CIRS/VIP treatment protocol associated with Dr. Shoemaker has generated interest but remains outside mainstream evidence-based medicine, and the proposed mechanism (VIP deficiency in CIRS) is a hypothesis, not an established diagnosis. The profound vasodilation effect of VIP at physiologically active doses means that anyone experimenting with injectable VIP is taking a meaningful hypotension risk that can manifest rapidly. Net: the most pharmacologically rich neuropeptide in this category, but practically unavailable as a useful self-administered compound given the pharmacokinetics and hypotension risk.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What VIP is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>A practical injectable compound — the two-minute plasma half-life makes sustained systemic effects from peripheral injection mechanistically implausible</li>
              <li>The same as aviptadil — the synthetic analog has different stability and is what clinical trials have actually studied</li>
              <li>Proven to work for CIRS or immune modulation in controlled human trials — the CIRS protocol is hypothesis-driven and not mainstream medicine</li>
              <li>Low-risk to self-inject — rapid profound vasodilation and hypotension are real consequences of VIP at active doses</li>
              <li>An approved therapeutic in any form in the US — there is no FDA approval for native VIP</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>One of the most broadly distributed regulatory peptides — gut, immune, brain, lung, and vascular tissue all express VIP receptors</li>
              <li>The GI-immune axis role is genuinely relevant to understanding intestinal inflammation and motility regulation</li>
              <li>Aviptadil has been in clinical trials for respiratory failure — demonstrates therapeutic plausibility in the VIP pathway</li>
              <li>CIRS research has brought VIP into broader awareness as a potential immune system regulator, even if the evidence is preliminary</li>
              <li>The anti-inflammatory signaling through immune cells is mechanistically distinct from most community peptides</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
